Aprepitant

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Definition
This section has been translated automatically.

Antiemetic, neurokinin-1 (NK1) antagonist.

Half-life
This section has been translated automatically.

9-13 hours

Pharmacodynamics (Effect)
This section has been translated automatically.

Blockade of NK-1 receptors in the brain and enhancement of the antiemetic effect of 5-HT3 receptor antagonists as well as of dexamethasone in antiemetic combination therapies Aprepitant also has an antipruritic effect.

Indication
This section has been translated automatically.

Prevention of acute and refractory nausea/vomiting in highly emetogenic cisplatin-based chemotherapy, as part of a combination therapy.

As an individual healing trial in therapy-resistant Prurigo nodularis.

Pregnancy/nursing period
This section has been translated automatically.

Should not be used during pregnancy (insufficient data available). Contraindicated during lactation.

Dosage and method of use
This section has been translated automatically.

125 mg p.o. once/day on day 1. 80 mg p.o. each on day 2 and 3.

Undesirable effects
This section has been translated automatically.

Occasionally/rarely: loss of appetite, weight gain. Rarely disorientation, euphoria, headache, dizziness, acne, photosensitivity, erythema exsudativum multiforme, Stevens Johnson syndrome.

Contraindication
This section has been translated automatically.

Do not use simultaneously with pimozide, terfenadine, astemizole or cisapride. Do not use in children (insufficient data available).

Preparations
This section has been translated automatically.

Emend

Literature
This section has been translated automatically.

  1. Fostini AC et al (2013) Prurigo nodularis: an update on etiopathogenesis and therapy. J Dermatologist Treat 24:458-462

Outgoing links (2)

Antiemetics; Nodular prurigo;

Authors

Last updated on: 29.10.2020